Eltrombopag
- Generic Name
- Eltrombopag
- Brand Names
- Promacta, Revolade
- Drug Type
- Small Molecule
- Chemical Formula
- C25H22N4O4
- CAS Number
- 496775-61-2
- Unique Ingredient Identifier
- S56D65XJ9G
- Background
Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood. Eltrombopag has also bee...
- Indication
Thrombopoietin receptor agonists are pharmaceutical agents that stimulate platelet production in the bone marrow. In this, they differ from the previously discussed agents that act by attempting to curtail platelet destruction.
- Associated Conditions
- Chronic immune thrombocytopenia, Severe Aplastic Anemia (SAA), Thrombocytopenia
- Associated Therapies
- First-line Therapy
Outcomes in Bone Marrow Aplasia.
- First Posted Date
- 2024-07-10
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 3
- Registration Number
- NCT06493981
The Efficacy and Safety of HCQ Plus TPO-RA in ANA Positive ITP
- Conditions
- Interventions
- First Posted Date
- 2024-06-28
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Yunfeng Cheng
- Target Recruit Count
- 126
- Registration Number
- NCT06479291
- Locations
- 🇲🇴
Dr. Stanley Ho Medical Foundation, Macau, Macau
🇨🇳Shanghai Jinshan Hospital, Shanghai, Shanghai, China
🇨🇳Wusong Hospital, Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
Efficacy and Safety of Eltrombopag for Refractory Thrombocytopenia Associated With Connective Tissue Disease
- Conditions
- Interventions
- First Posted Date
- 2024-06-14
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 52
- Registration Number
- NCT06458803
High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly
- First Posted Date
- 2024-04-03
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT06345495
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Eltrombopag for Treatment of Fanconi Anemia
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Julian Sevilla
- Target Recruit Count
- 8
- Registration Number
- NCT06045052
- Locations
- 🇪🇸
Hospital Infantil Universitario Niño Jesús (HIUNJ), Madrid, Spain
Immune Thrombocytopenia Management in Adults
- Conditions
- Interventions
- First Posted Date
- 2023-05-16
- Last Posted Date
- 2023-05-16
- Lead Sponsor
- Nahda University
- Target Recruit Count
- 467
- Registration Number
- NCT05861297
- Locations
- 🇪🇬
EL-Kasr elineiy, Cairo, Egypt
A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids
- Conditions
- Interventions
- First Posted Date
- 2022-12-16
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 150
- Registration Number
- NCT05653219
- Locations
- 🇺🇸
Yuma Regional Medical Center, Yuma, Arizona, United States
🇺🇸Community Cancer Institute, Clovis, California, United States
🇺🇸Compassionate Care Res Group Inc, Fountain Valley, California, United States
A Randomized Trial Comparing Optimized rhTPO Treatment With Eltrombopag Treatment in Pre-treated ITP Pts
- Conditions
- Interventions
- First Posted Date
- 2022-10-18
- Last Posted Date
- 2024-07-26
- Target Recruit Count
- 157
- Registration Number
- NCT05583838
- Locations
- 🇨🇳
The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
🇨🇳the Second Hospital of HeBei Medical University, Shijiazhuang, Hebei, China
🇨🇳North China University of Science and Technology Affiliated Hospital, Tangshan, Heibei, China
The Combination of ATRA and Eltrombopag as the Treatment of Steroid-resistant/Relapse ITP Based on MSC-C5b-9
- Conditions
- Interventions
- First Posted Date
- 2022-06-30
- Last Posted Date
- 2023-11-24
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 96
- Registration Number
- NCT05438875
- Locations
- 🇨🇳
Peking University Insititute of Hematology, Peking University People's Hospital, Beijing, Beijing, China
🇨🇳Department of Hematology, Beijing Friendship Hospital, Capital Medical University, Beijing, China
🇨🇳Department of Hematology, Beijing Hospital, Beijing, China
Zanubrutinib and Eltrombopag as Second-line Treatment in Adults With Primary Immune Thrombocytopenia
- Conditions
- Interventions
- First Posted Date
- 2022-05-11
- Last Posted Date
- 2022-05-11
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT05369377
- Locations
- 🇨🇳
Peking University Insititute of Hematology, Peking University People's Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.